U.S. Markets closed

Heat Biologics, Inc. (HTBX)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
4.4600-0.2400 (-5.11%)
At close: 4:00PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close4.7000
Bid4.4500 x 800
Ask4.6400 x 1100
Day's Range4.4500 - 4.7000
52 Week Range4.2200 - 17.0000
Avg. Volume270,395
Market Cap113.272M
Beta (5Y Monthly)0.28
PE Ratio (TTM)N/A
EPS (TTM)-1.3650
Earnings DateAug 05, 2021 - Aug 09, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est20.67
  • Zacks Small Cap Research

    HTBX: Third Quarter Results

    By John Vandermosten, CFA NASDAQ:HTBX READ THE FULL HTBX RESEARCH REPORT Heat Biologics, Inc. (NASDAQ:HTBX) reported third quarter 2021 results on November 10, 2021 and filed its Form 10-Q with the SEC. Highlights for the third quarter ending September 30, 2021 and to date include: ➢ Groundbreaking for San Antonio facility - August 2021 ➢ Formation of and new additions to Biothreat Advisory Board

  • GlobeNewswire

    Heat Biologics Provides Third Quarter 2021 Business Update

    DURHAM, N.C., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (“Heat”) (NASDAQ: HTBX), today provided strategic, financial, and operational updates for the third quarter ended September 30, 2021. Jeff Wolf, Chief Executive Officer of Heat, commented, “Our clinical and preclinical programs are progressing well. In September, we expanded dosing in our Phase 1 clinical trial of monoclonal antibody PTX-35 in patients with solid tumors, and are planning a clinical development pathway to utiliz

  • GlobeNewswire

    Heat Biologics Appoints Paul Tebbey as Senior Vice President of Product Development and Portfolio Strategy

    DURHAM, N.C., Oct. 06, 2021 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (“Heat”) (NASDAQ: HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, today announced the appointment of Paul Tebbey, Ph.D. as Senior Vice President of Product Development and Portfolio Strategy. Dr. Tebbey is a pharmaceutical development strategy leader with over 25 years of healthcare and management experience across the biotechnology and pharmaceutic